| 631 |
ROLE OF IL-6, sIL-6R, IL-β, TNF-α, AND B2M IN PATHOPHYSIOLOGY AND PROGNOSIS OF MULTIPLE MYELOMA |
2007 |
| 632 |
ROLE OF IL-6, sIL-6R, IL-β, TNF-α, AND B2M IN PATHOPHYSIOLOGY AND PROGNOSIS OF MULTIPLE MYELOMA |
2007 |
| 633 |
ROLE OF IL-6, sIL-6R, IL-β, TNF-α, AND B2M IN PATHOPHYSIOLOGY AND PROGNOSIS OF MULTIPLE MYELOMA |
2007 |
| 634 |
ROLE OF IL-6, sIL-6R, IL-β, TNF-α, AND B2M IN PATHOPHYSIOLOGY AND PROGNOSIS OF MULTIPLE MYELOMA |
2007 |
| 635 |
ROLE OF IL-6, sIL-6R, IL-β, TNF-α, AND B2M IN PATHOPHYSIOLOGY AND PROGNOSIS OF MULTIPLE MYELOMA |
2007 |
| 636 |
Serum lipid, Apo E genotypes and tumer necrosis factor alpha in Psoriatic arthritis patients: In relation to disease activity |
2007 |
| 637 |
Serum lipid, Apo E genotypes and tumer necrosis factor alpha in Psoriatic arthritis patients: In relation to disease activity |
2007 |
| 638 |
Serum lipid, Apo E genotypes and tumer necrosis factor alpha in Psoriatic arthritis patients: In relation to disease activity |
2007 |
| 639 |
Serum lipid, Apo E genotypes and tumer necrosis factor alpha in Psoriatic arthritis patients: In relation to disease activity |
2007 |
| 640 |
Serum lipid, Apo E genotypes and tumer necrosis factor alpha in Psoriatic arthritis patients: In relation to disease activity |
2007 |
هل لديك سؤال ؟
